Effects and safety of lanthanum carbonate in end stage renal disease patients with hyperphosphatemia: A meta-analysis-system review of lanthanum carbonate

摘要

Aim: To assess the effect and safety of lanthanum carbonate (LC) for hypophosphatemia in patients with end-stage renal disease (ESRD). Methods: According to the collaborative review group search strategy, we searched MEDLINE (1996 to 2012.12); EBCO (1996 to 2012.12), and CNKI. We searched Chinese journals by hand. We conducted quality assessment and data extraction by two independent investigators. Meta-analysis was conducted by RevMan 5.0. Results were expressed as OR with 95% confidence interval for dichotomous outcomes and WMD with 95% confidence interval for continuous outcomes. Result: We identified 16 reports which might meet the inclusion criteria for our review. The meta-analysis showed that LC was superior to placebo in treating hypophosphatemia of end-stage renal disease patients (OR=5.46, 95% CI: 2.37 to 2.61, p<0.005) and as efficient as conventional therapies (WMD=-0.06, 95% CI: -0.27 to 0.15, p=0.57). The incidence of all adverse events was similar between LC- and placebo-treated patients (OR=1.16, 95% CI: 0.79 to 1.68, p=0.45). Conclusion: Lanthanum carbonate is well effective and tolerated in treating hyperphosphatemia of ESRD patients. Lanthanum carbonate is not likely to cause hypercalcemia compared to calcium-based phosphate binders.